CREG Antibody (30R): sc-100695

CREG Antibody (30R) is a mouse monoclonal IgG1 kappa light chain antibody that detects CREG protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Anti-CREG antibody (30R) is available as the non-conjugated format. CREG protein, known as the cellular repressor of E1A-stimulated genes, plays a crucial role in regulating gene expression and cellular differentiation, particularly in the context of adenoviral infection. CREG protein functions by antagonizing the transcriptional activation and cellular transformation induced by the adenovirus E1A protein, which both activates and represses gene expression to promote cellular proliferation. CREG protein′s ability to bind to the TATA-binding protein, TBP, was initially identified through a yeast two-hybrid screen, highlighting CREG′s importance in transcriptional regulation. CREG protein contains binding sites for E2F, a pivotal transcriptional regulator of cell cycle progression, which are essential for repressive action on the adenovirus E2 promoter. This interaction underscores CREG′s role in inhibiting E2F-mediated activation, thereby contributing to the control of cell growth and differentiation. CREG protein is a secreted glycoprotein broadly expressed in adult tissues and regulated during embryonic development, enhancing the differentiation of mouse embryonic stem cells and human NTERA-2 cells. CREG protein′s activity may be vital for the transcriptional control of cellular processes, making anti-CREG antibody (30R) an important tool for researchers studying gene regulation and cellular differentiation in human tissues.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CREG Antibody (30R) References:

1. The secreted glycoprotein CREG enhances differentiation of NTERA-2 human embryonal carcinoma cells.  |  Veal, E., et al. 2000. Oncogene. 19: 2120-8. PMID: 10815803
2. Analysis of E1A-mediated growth regulation functions: binding of the 300-kilodalton cellular product correlates with E1A enhancer repression function and DNA synthesis-inducing activity.  |  Stein, RW., et al. 1990. J Virol. 64: 4421-7. PMID: 2143544
3. Cellular targets for transformation by the adenovirus E1A proteins.  |  Whyte, P., et al. 1989. Cell. 56: 67-75. PMID: 2521301
4. Mechanism of active transcriptional repression by the retinoblastoma protein.  |  Weintraub, SJ., et al. 1995. Nature. 375: 812-5. PMID: 7596417
5. A cellular repressor of E1A-stimulated genes that inhibits activation by E2F.  |  Veal, E., et al. 1998. Mol Cell Biol. 18: 5032-41. PMID: 9710587

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CREG Antibody (30R) has 2 citations in a variety of scientific publications.

Primary antibodies like Anti-CREG Antibody (30R) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CREG Antibody (30R) Specifications

Alternate Product Name: CREG

Product Clone Name: 30R

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 121-221

Epitope Target: CREG

Epitope Species: human

Product Reactivity/Detection: CREG

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 100 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for CREG Antibody (30R): N/A